secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2026-07-30T10:48:32+00:00
Accession:  0000872589-26-000023
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron Q2 2026 revenue up 17% to $4.3B; non-GAAP EPS $14.29 beats; Dupixent sales up 38%
--------------------------------------------------------------------------------

- Total revenues $4.291B (+17% YoY); GAAP EPS $12.23 (incl. $1.02 IPR&D charge); non-GAAP EPS $14.29 (+11%).
- Dupixent global net sales (Sanofi) up 38% to $6.0B; EYLEA HD U.S. net sales up 52% to $596M; Libtayo global up 30% to $489M.
- Sanofi Development Balance fully repaid; collaboration profits to step up in Q3. Guidance raised: GAAP gross margin 78-79% (prior 77-78%).
- Cemdisiran NDA accepted for gMG with priority review; FDA target action date Nov 2026.
- Share repurchases $1.2B in Q2; $2.0B in H1; dividend $0.94/share declared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/0000872589-26-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000087258926000023/regn-20260730.htm
  HTML page:      https://secwatch.observer/filing/0000872589-26-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer